435 related articles for article (PubMed ID: 30024656)
21. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma.
Uematsu A; Kido K; Manabe E; Takeda H; Takahashi H; Hayashi M; Imai Y; Sawasaki T
Biochem Biophys Res Commun; 2018 Jan; 495(3):2289-2295. PubMed ID: 29284118
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenomics and chemical library screens reveal a novel SCF
Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
[TBL] [Abstract][Full Text] [Related]
23. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
Hu L; Li B; Chen G; Song D; Xu Z; Gao L; Xi M; Zhou J; Li L; Zhang H; Feng Q; Wang Y; Lu K; Lu Y; Bu W; Wang H; Wu X; Zhu W; Shi J
J Exp Clin Cancer Res; 2020 Jun; 39(1):105. PubMed ID: 32517809
[TBL] [Abstract][Full Text] [Related]
24. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
Berenson JR; Ma HM; Vescio R
Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
[TBL] [Abstract][Full Text] [Related]
25. Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation.
Xie H; Gu Y; Wang W; Wang X; Ye X; Xin C; Lu M; Reddy BA; Shu P
Sci Rep; 2020 Jan; 10(1):766. PubMed ID: 31964975
[TBL] [Abstract][Full Text] [Related]
26. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
[TBL] [Abstract][Full Text] [Related]
27. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
[TBL] [Abstract][Full Text] [Related]
28. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
29. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
[TBL] [Abstract][Full Text] [Related]
30. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
31. Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma.
Zhang H; Chen J; Zhang M; Zhao M; Zhang L; Liu B; Wang S
Med Oncol; 2022 Feb; 39(5):55. PubMed ID: 35150316
[TBL] [Abstract][Full Text] [Related]
32. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
33. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
34. Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma.
Zaal EA; de Grooth HJ; Oudaert I; Langerhorst P; Levantovsky S; van Slobbe GJJ; Jansen JWA; Menu E; Wu W; Berkers CR
Mol Omics; 2022 Jan; 18(1):19-30. PubMed ID: 34879122
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.
Leng Y; Hu X; Li L; Nkwocha J; Satta T; Sharma K; Kmeiciak M; Zhou H; Zhang Z; Zhou L; Chen W; Grant S
Hematol Oncol; 2022 Dec; 40(5):999-1008. PubMed ID: 35789025
[TBL] [Abstract][Full Text] [Related]
36. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
[TBL] [Abstract][Full Text] [Related]
37. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.
Sung B; Kunnumakkara AB; Sethi G; Anand P; Guha S; Aggarwal BB
Mol Cancer Ther; 2009 Apr; 8(4):959-70. PubMed ID: 19372569
[TBL] [Abstract][Full Text] [Related]
38. Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.
Fristedt Duvefelt C; Lub S; Agarwal P; Arngården L; Hammarberg A; Maes K; Van Valckenborgh E; Vanderkerken K; Jernberg Wiklund H
Oncotarget; 2015 Aug; 6(24):20621-35. PubMed ID: 26036313
[TBL] [Abstract][Full Text] [Related]
39. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.
Viziteu E; Klein B; Basbous J; Lin YL; Hirtz C; Gourzones C; Tiers L; Bruyer A; Vincent L; Grandmougin C; Seckinger A; Goldschmidt H; Constantinou A; Pasero P; Hose D; Moreaux J
Leukemia; 2017 Oct; 31(10):2104-2113. PubMed ID: 28186131
[TBL] [Abstract][Full Text] [Related]
40. KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-κB signaling pathway.
Song IS; Jeong YJ; Nyamaa B; Jeong SH; Kim HK; Kim N; Ko KS; Rhee BD; Han J
BMB Rep; 2015 Oct; 48(10):571-6. PubMed ID: 25772758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]